Send us Fan Mail

Dr. Elise Fallucco continues this series on non-stimulant medication for ADHD and shares practical tips about using Norepinephrine Reuptake Inhibitors (NRIs): viloxazine ER (Qelbree) and atomoxetine (Strattera) for pediatric clinicians.

Who can benefit from NRIs? What are the potential benefits, drawbacks, and side effects?

Working through the case of a 12-year-old girl with inattentive ADHD and anxiety who cannot tolerate methylphenidate or amphetamine , she explains why she generally prefers Viloxazine ER (Qelbree)

• FDA approval for ADHD in children ages 6+
• Quicker onset (often within 1–2 weeks vs 4–6 weeks for atomoxetine)
• Better tolerability
• More straightforward dosing
• Unlike Atomoxetine (Strattera), you can dose this medication without worrying about significant genetic variability in drug metabolism

00:00 NRIs for ADHD

00:38 When to Use

01:07 Case Introduction

02:51 Stimulant Trials Fail

04:09 Considering NRIs

04:30 Why Qelbree First

05:51 Atomoxetine Caveats

07:23 Treating Sophie

08:45 Clinical Pearls Recap

09:50 Wrap Up and CME

Check out our website PsychEd4Peds.com for more resources!
Follow us on Instagram @psyched4peds

Check out our NEW CME Audio-based, on-demand CME Course online at:

Pediatric Mental Health CME Toolkit - Cracking the ADHD Code: Essentials for Pediatric Clinicians.

https://ce.nemours.org/content/podcast-series-cracking-adhd-code-essential-skills-pediatric-clinicians#group-tabs-node-course-default1